Growing old with antiretroviral therapy or elderly people in antiretroviral therapy: two different profiles of comorbidity?

Table 1 Baseline characteristics of 1394 subjects aged ≥ 50 years enrolled in the SCOLTA Project between 2013 and 2021

Patients’ characteristics	ART exposure
	≤ 3 years		> 3 years		p
	N	%	N	%	p
Total	323	23.2	1071	76.8	–
Age, years (mean, SD)	57.1 ± 6.3		57.5 ± 6.6		0.24
Sex
Male	256	79.3	806	75.3	0.14
Female	67	20.7	265	24.7	0.14
Caucasian ethnicity	304	94.1	1033	96.4	0.06
BMI, Kg/m² (mean, SD)	24.3 ± 3.7		24.9 ± 4.2		0.047
Risk factor for HIV acquisition
IDU	41	12.7	334	31.2	< 0.0001
Heterosexual	140	43.3	377	35.2
Homosexual	106	32.8	236	22.0
Other/unknown	36	11.2	124	11.6
HCV positive	44	14.6	388	37.6	< 0.0001
CDC Stage
A	167	51.7	453	42.3	0.14
B	68	21.0	344	32.1
C	88	27.4	274	25.6
Detectable HIVRNA (exp)	23	13.4	140	13.1	0.91
CD4 + count, cell/mL (median, IQR)	399	211–642	634	442–868	< 0.0001
eGFR, mL/min (mean, SD)	89.3 ± 24.3		84.8 ± 22.6		0.002
Comorbidities
0	76	23.5	92	8.6	< 0.0001
1	94	29.1	280	26.1
≥ 2	153	47.4	699	65.3

ART antiretroviral treatment, eGFR estimated glomerular filtration rate, HCV human C hepatitis virus, IDU intravenous drug use, IQR interquartile range, SD standard deviation

ISSN: 1471-2334